Idarubicin Accord

Idarubicin, the active ingredient in Idarubicin Accord, is an anthracycline antibiotic presented as an injectable solution for intravenous use. It is employed in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia in adult patients and is part of standard induction chemotherapy protocols.

GNH USA supplies Idarubicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance. The product meets EU quality standards and is available for bulk procurement.

Idarubicin is an anthracycline used in the treatment of acute leukemias.

Acute Myeloid Leukemia (AML): induces remission as part of induction chemotherapy. Acute Lymphoblastic Leukemia (ALL): contributes to disease control in adult patients. Relapsed or refractory AML: provides an alternative option when prior regimens have failed.

Idarubicin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during treatment. - Alopecia (hair loss): reversible loss of scalp and body hair. - Myelosuppression (low blood counts): decreased white cells, red cells, and platelets. - Fatigue and weakness: persistent lack of energy affecting daily activities.

Serious or Rare Side Effects: - Cardiotoxicity, including reduced left ventricular function: may lead to heart failure. - Severe neutropenia with risk of infection: markedly low neutrophil counts. - Febrile neutropenia: fever accompanying neutropenia requiring urgent care. - Secondary acute myeloid leukemia or myelodysplastic syndrome: rare therapy‑related hematologic malignancies.

When using Idarubicin, several precautions should be observed to minimize risks. - Cardiac monitoring: assess baseline and periodic left ventricular ejection fraction. - Hematologic monitoring: perform regular complete blood counts to detect myelosuppression. - Liver function assessment: evaluate hepatic enzymes before and during therapy. - Renal function assessment: monitor creatinine clearance, especially in patients with impaired kidneys. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use of other anthracyclines: markedly increases cardiotoxic risk and cumulative dose limits. - Trastuzumab or other HER2‑targeted agents: synergistic cardiac toxicity requiring cardiac function monitoring. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma levels of idarubicin, heightening systemic toxicity.

Moderate Interactions (Monitor Closely): - Myelosuppressive agents (e.g., cyclophosphamide, cytarabine): may exacerbate bone‑marrow suppression, necessitating closer blood count surveillance. - Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): increase risk of renal impairment when combined with idarubicin. - QT‑prolonging medications (e.g., quinidine, sotalol): may augment cardiac arrhythmia risk, warranting ECG monitoring.